Disc Medicine Inc

IRON

Company Profile

  • Business description

    Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

  • Contact

    321 Arsenal Street
    Suite 101
    WatertownMA02472
    USA

    T: +1 617 674-9274

    https://www.discmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    155

Stocks News & Analysis

stocks

Lowering profit forecasts on Aussie airlines

The impact of the oil price surge.
stocks

AI isn’t an economic moat killer, but it will disrupt industries

How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks

AI lands a blow on some Aussie stocks – yet stands to benefit others

AI is reshaping ASX tech moats - but some are more insulated than others.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,592.90103.70-1.19%
CAC 407,726.2060.580.79%
DAX 4022,653.86273.671.22%
Dow JONES (US)46,208.47631.001.38%
FTSE 1009,894.1524.18-0.24%
HKSE24,731.42348.951.43%
NASDAQ21,946.76299.151.38%
Nikkei 22551,840.82325.330.63%
NZX 50 Index12,701.75197.97-1.53%
S&P 5006,581.0074.521.15%
S&P/ASX 2008,401.90102.70-1.21%
SSE Composite Index3,838.2124.930.65%

Market Movers